These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20355158)

  • 1. SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control.
    Reichel C; Kulovics R; Jordan V; Watzinger M; Geisendorfer T
    Drug Test Anal; 2009 Jan; 1(1):43-50. PubMed ID: 20355158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in doping testing for erythropoietin.
    Reichel C
    Anal Bioanal Chem; 2011 Aug; 401(2):463-81. PubMed ID: 21637931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARCOSYL-PAGE: a new method for the detection of MIRCERA- and EPO-doping in blood.
    Reichel C; Abzieher F; Geisendorfer T
    Drug Test Anal; 2009 Nov; 1(11-12):494-504. PubMed ID: 20355164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desialylation improves the detection of recombinant erythropoietins in urine samples analyzed by SDS-PAGE.
    Desharnais P; Naud JF; Ayotte C
    Drug Test Anal; 2013; 5(11-12):870-6. PubMed ID: 23720238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc-fragment removal allows the EPO-Fc fusion protein to be detected in blood samples by IEF-PAGE.
    Postnikov P; Krotov G; Mesonzhnik N; Efimova Y; Rodchenkov G
    Drug Test Anal; 2015; 7(11-12):999-1008. PubMed ID: 26695487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application.
    Okano M; Sato M; Kaneko E; Kageyama S
    Drug Test Anal; 2011; 3(11-12):798-805. PubMed ID: 22012825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interference of heparin on IEF-PAGE of erythropoietins.
    Reichel C; Benetka E; Geisendorfer T; Scheiblhofer V; Abzieher F
    Drug Test Anal; 2010; 2(11-12):568-75. PubMed ID: 21204288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practicing IEF-PAGE of EPO: the impact of detergents and sample application methods on analytical performance in doping control.
    Reichel C
    Drug Test Anal; 2010; 2(11-12):603-19. PubMed ID: 21204292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels.
    Kohler M; Ayotte C; Desharnais P; Flenker U; Lüdke S; Thevis M; Völker-Schänzer E; Schänzer W
    Int J Sports Med; 2008 Jan; 29(1):1-6. PubMed ID: 18050057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of single doses of methoxypolyethylene glycol-epoetin beta (CERA, Mircera™) and epoetin delta (Dynepo™) on isoelectric erythropoietin profiles and haematological parameters.
    Dehnes Y; Hemmersbach P
    Drug Test Anal; 2011 May; 3(5):291-9. PubMed ID: 21387570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomagnetic beads-based isolation of erythropoietins from urine and blood for sports anti-doping control.
    Desharnais P; Naud JF; Ayotte C
    Drug Test Anal; 2017 Nov; 9(11-12):1744-1752. PubMed ID: 28994210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of AMGEN clone 9G8A anti-Epo antibody for application in doping control.
    Reichel C; Benetka W; Lorenc B; Thevis M
    Drug Test Anal; 2016 Nov; 8(11-12):1131-1137. PubMed ID: 27552163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights for identification of doping with recombinant human erythropoietin micro-doses after high hydration.
    Martin L; Ashenden M; Bejder J; Hoffmann M; Nordsborg N; Karstoft K; Morkeberg J; Sharpe K; Lasne F; Marchand A
    Drug Test Anal; 2016 Nov; 8(11-12):1119-1130. PubMed ID: 27390252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of high intensity exercise on isoelectric profiles and SDS-PAGE mobility of erythropoietin.
    Voss S; Lüdke A; Romberg S; Schänzer E; Flenker U; deMarees M; Achtzehn S; Mester J; Schänzer W
    Int J Sports Med; 2010 Jun; 31(6):367-71. PubMed ID: 20419620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing.
    Reichel C; Thevis M
    Drug Test Anal; 2012 Nov; 4(11):818-29. PubMed ID: 22764129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of recombinant EPO in blood and urine samples with EPO WGA MAIIA, IEF and SAR-PAGE after microdose injections.
    Dehnes Y; Shalina A; Myrvold L
    Drug Test Anal; 2013; 5(11-12):861-9. PubMed ID: 24190107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defending Dynepo detection.
    Gmeiner G; Reichel C; Kulovics R; Scheiblhofer V
    Drug Test Anal; 2010; 2(11-12):526-32. PubMed ID: 21204285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An optimized SDS-PAGE protocol with a new blotting system for the initial testing procedure of ESAs in doping control.
    Martin L; Martin JA; Audran M; Marchand A
    Drug Test Anal; 2022 Jan; 14(1):181-187. PubMed ID: 33269539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of intact recombinant human erythropoietins applied in doping by means of planar gel electrophoretic techniques and matrix-assisted laser desorption/ionisation linear time-of-flight mass spectrometry.
    Stübiger G; Marchetti M; Nagano M; Reichel C; Gmeiner G; Allmaier G
    Rapid Commun Mass Spectrom; 2005; 19(5):728-42. PubMed ID: 15700237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The overlooked difference between human endogenous and recombinant erythropoietins and its implication for sports drug testing and pharmaceutical drug design.
    Reichel C
    Drug Test Anal; 2011; 3(11-12):883-91. PubMed ID: 22140023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.